ExPEC10V

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| type = vaccine

| image =

| image_class =

| alt =

| caption =

| target = Escherichia coli

| vaccine_type = conjugate

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Intramuscular injection

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| PubChem =

| DrugBank =

| synonyms = ExPEC10-V; ExPEC-10V; ExPECV10; ExPEC-V10; VAC-52416; VAC52416; JNJ-69968054; JNJ69968054

}}

ExPEC10V, also known as VAC-52416 or JNJ-69968054, is a vaccine against Escherichia coli infection.{{cite web | title=VAC 52416 | website=AdisInsight | date=28 April 2023 | url=https://adisinsight.springer.com/drugs/800053991 | access-date=28 February 2025}}{{cite journal | vauthors = Doiron RC, Cotechini T, Nickel JC | title = It's Time to Embrace Vaccination as We Enter the Postantibiotic Era of Recurrent Urinary Tract Infection Management | journal = The Journal of Urology | volume = 211 | issue = 6 | pages = 797–799 | date = June 2024 | pmid = 38704743 | doi = 10.1097/JU.0000000000003969 }} It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by Janssen Pharmaceuticals. As of April 2023, ExPEC10V is in phase 3 clinical trials. It is under development towards approval in the United States, Europe, and Japan. The vaccine is a 10-valent form of the earlier ExPEC4V.